Disease-modifying epilepsy medication

Antiepileptogenesis, i.e., the prevention of epilepsy following brain injury firstly requires the identification of biomarkers for epileptogenesis and epilepsy.¹ The time window and duration of treatment will then need to be determined.¹ However, in contrast to conventional clinical trials of antiseizure medications, the duration must be sufficiently long to enable disruption of the epileptogenic process and observe the objective outcome in an adequate proportion of patients.¹

Reference:

1.French JA, Bebin M, Dichter MA, et al. Antiepileptogenesis and disease modification: clinical and regulatory issues. Epilepsia Open 2021; 6 (3): 483–492.